A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)
Status:
Recruiting
Trial end date:
2023-03-30
Target enrollment:
Participant gender:
Summary
This study will assess the antitumor activity, safety, tolerability, and pharmacokinetics
(PK) of the Mesenchymal-epithelial Transition Factor (MET) inhibitor tepotinib combined with
the 3rd generation EGFR inhibitor osimertinib in participants with advanced or metastatic
non-small cell lung cancer (NSCLC).